New Drug Cuts Prostate Cancer Relapse Risk By One-Third

Thousands of men facing advanced prostate cancer now have renewed hope as a new drug significantly reduces relapse risk. This breakthrough treatment lowers the chance of the disease returning by nearly a third and slows its deadly spread.

For many patients, surgical removal of the prostate remains a critical first step. Yet, approximately half of these cases eventually see the cancer return despite the initial success of the operation.

Standard medical practice relies on androgen deprivation therapy, or ADT. These medications suppress testosterone production, starving tumors of the fuel they need to grow and shrink.

Now, US researchers have published data indicating that combining apalutamide, sold under the brand name Erleada, with standard ADT extends life and improves health outcomes.

Experts presented these findings at the American Society for Clinical Oncology annual meeting. They stated the drug clearly improves survival for surgical patients facing a high risk of recurrence.

Data from the phase 3 PROTEUS trial shows that adding apalutamide to standard ADT significantly delays disease progression in high-risk patients. The study involved over 2,100 men with an average age of 66 from 18 nations.

Participants received six months of ADT before and after surgery. Half the group took apalutamide while the other half received a placebo.

Five years later, the apalutamide group faced a 29 percent lower risk of cancer returning. They also remained free from progression for nearly five years compared to roughly three years for the placebo group.

The treatment also cut the risk of cancer spreading by about 20 percent with minimal additional side effects. Urinary tract infections were common in both groups, while rashes were the primary reason for stopping the drug.

Researchers are now investigating the duration of effectiveness and the drug's impact on quality of life. Simon Grieveson, Assistant Director of Research at Prostate Cancer UK, called the results exciting for men with high-risk localized or locally advanced cancer.

He noted that the treatment gives patients more time with loved ones and greater assurance against recurrence. However, he emphasized caution regarding serious side effects and the danger of over-treating some men.

Further research is essential to identify exactly which patients benefit most from this additional therapy. Prostate cancer is the most common cancer in the UK, affecting one in eight men.

The nation sees around 63,000 new cases and 12,000 deaths annually. These developments arrive just days after government advisers rejected a major national screening program.

The Daily Mail continues to campaign against needless deaths and supports a national screening initiative. This program would initially target high-risk groups, including Black men, those with family histories, or specific genetic mutations.